@celltherapy
Account based inCanada
About this account
- Account based in
- Canada
- Connected via
- Canada Android App
Account-level information from X, not a live location or the device used for a specific post.
Executive, entrepreneur, advisor, director, consultant, analyst, author, and commentator in the advanced therapies & cell-based advanced therapies industry.
Vancouver
Joined June 2008
- Tweets8K
- Following2.6K
- Followers6.8K
- Likes2.7K
Lee Buckler retweeted
This month's @BCAbloodcenters #AdvancedTherapy News is now out featuring the @AllofUsResearch program, decentralized manufacturing, outpatient #celltherapy admin, and much more!
mailchi.mp/22a03f70c083/adva…
Thanks to @getbiolinked for sponsoring + @accellix for the special offer.
Introducing IRO®, the new standard in CGT #manufacturing technology.
Manufacturing remains a critical barrier to scaling CGTs, limiting the clinical and commercial impact of this lifesaving new class of therapies.
That’s why we developed IRO®.
➡️ oribiotech.com/press-release…
Today we introduce the CellSeal® CryoCase™ closed-system rigid container at the @ISCTglobal Conference in Vancouver.
Read the press release for more details.
go.biolifesolutions.com/l/10…
Lee Buckler retweeted
Join the Decentralized Manufacturing Working Group tomorrow for a discussion on Regulatory Challenges! events.teams.microsoft.com/e…
Lee Buckler retweeted
Did you catch this @BioProcessIntl piece by Brent Morse and Alicja Fiedorowicz? "Analytical Considerations for Gene-Modified Hematopoietic Stem and Progenitor Cell Therapies: Part 1 — In-Process and Drug Product Control."
Read now, here! bioprocessintl.com/cell-ther…
Lee Buckler retweeted
More momentum on the #POC manufacturing front. Enter, regional blood banks. @GalapagosGlobal @BCAbloodcenters glpg.com/press-releases/gala…
Lee Buckler retweeted
Aiming to decentralize CAR-T manufacturing, @GalapagosGlobal partners with largest US blood supply network - endpts.com/aiming-to-decentr…
Fulfilling the promise of cell & gene therapies through manufacturing (Part I) fiercepharma.com/manufacturi…
Please note @LeeBuckler4 is a fake account. Please report it and block it. #fakeaccount. Thank you @DrPHanley for alerting me.
NY Governor Releases Request for Proposals for State-of-the-Art Cell and Gene Therapy Hub on Long Island.
More Than $150M Available Builds on Governor’s Commitment to Boosting Fast Growing Sectors Like Life Sciences — Including State Commitment to Establishing Two Cell and Gene Therapy Hubs
New Hub Will Help to Position New York State as National Leader in Cell and Gene Therapies
governor.ny.gov/news/governo…
Wow. Thank you #sfo for transforming the airport experience. 🙏🏼🧘🏼♂️💙
If you have not participated in the @US_FDA's crowdsourcing initiative: Envisioning the Future for Biological Products, then get to it! You have 2 days left.
Bring your insights and expertise to CBER’s crowdsourcing community designed to share ideas, solutions, and visions for the future of biologics. The goal of this crowdsourcing initiative is to gather external ideas on major advances in product development for CBER-regulated products, including novel products and product manufacturing methods that are likely to emerge in the next 3-10 years. fda-cber.ideascalegov.com/c/…
A panel of independent experts on Wednesday recommended that @FDACBER reject an experimental ALS #celltherapy, known as #NurOwn, developed by the biotech @BrainstormCell.
The FDA has until Dec. 8 to approve or reject the drug endpts.com/fda-panel-recomme…
On the 27th, the @FDACBER CTG Therapies Adv Comm will meet in open session to discuss and make recommendations on @BrainstormCell's biologics license application for debamestrocel (autologous bone marrow-derived MSC #celltherapy) for the treatment of amyotrophic lateral sclerosis (ALS).
fda.gov/advisory-committees/…
BioCardia unveils interim data that led it to stop PhIII enrollment of heart failure stem cell therapy - endpts.com/biocardia-unveils…
What is this the 3rd time around? Maybe they should have listened to the FDA the first time or second time.
_____
Mesoblast's CEO takes 30% pay cut to fund 3rd shot at cell therapy approval fiercebiotech.com/biotech/me…
Despite the obfuscating press release, the short of it for @biocardia $BCDA, is the DSMB did a futility analysis and concluded the ph 3 trial was unlikely to meet the PE but mgmt convinced them to pause the trial pending the 12-month outcomes analysis.
markets.businessinsider.com/…
If you've ever thought analytical technologies for #celltherapies are a black hole, then we aim to crowdsource you some answers. We've launched a project trying to shed some light on existing and up-and-coming analytical technologies.
Help us help you.
docs.google.com/forms/d/e/1F…
